This visceral drama felt like the definitive show of the first Trump presidency. But, argues Fiona Sturges, the further it’s ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

With cross-country expanding from three to four postseason divisions, the OHSAA on April 24 announced divisional alignments ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

EDT Gilead (GILD) down 3% at $102.98 after Q1 results, affirmed FY25 guidanceStay Ahead of the Market: Discover outperforming stocks and ...

Looking ahead, Gilead Sciences cut its full-year earnings outlook to $5.65 to $6.05 a share from a prior range of $5.95 to $6.35 a share. Analysts had been expecting full-year earnings of $6.22. The ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Thursday reported first-quarter earnings of $1.32 billion. The Foster City, California-based company said it had ...